Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
153 hedge funds and large institutions have $200M invested in Clovis Oncology, Inc. in 2019 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 66 increasing their positions, 33 reducing their positions, and 39 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 33
19% more call options, than puts
Call options by funds: $28.4M | Put options by funds: $23.8M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 167 → 153 (-14)
36% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 39
73% less capital invested
Capital invested by funds: $752M → $200M (-$552M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECP
Elk Creek Partners
Denver,
Colorado
|
+$16.6M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$13.6M |
| 3 |
Morgan Stanley
New York
|
+$13.3M |
| 4 |
Two Sigma Investments
New York
|
+$7.02M |
| 5 |
D.E. Shaw & Co
New York
|
+$6.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$35.1M |
| 2 |
O
OrbiMed
New York
|
-$28.4M |
| 3 |
SC
Samlyn Capital
New York
|
-$14.2M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.84M |
| 5 |
Rafferty Asset Management
New York
|
-$5.46M |
CLVS Hedge Fund Activity: Q3 2019 in Review
153 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2019, worth a combined $200M — down 73% from $752M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of CLVS and 25 opened new positions — a net loss of 14 holders — while 33 trimmed existing stakes and 66 added.
The largest buyer was Elk Creek Partners, adding an estimated $16.6M. The largest seller was State Street, cutting an estimated $35.1M.
- 153 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2019, down from 167 in Q2 2019.
- Funds reported $200M of Clovis Oncology, Inc. stock for Q3 2019, down 73% quarter-over-quarter.
- 25 funds opened new Clovis Oncology, Inc. positions in Q3 2019 and 39 closed out, a net change of -14 holders.
- The largest Clovis Oncology, Inc. buyer in Q3 2019 was Elk Creek Partners, an estimated $16.6M added.
- The largest Clovis Oncology, Inc. seller in Q3 2019 was State Street, an estimated $35.1M sold.
Based on aggregated 13F filings for Q3 2019.